Session: *Industry Symposium: FORWARD Open Label Study: Evaluating the Effectiveness of BOTOX® Compared to Topiramate for Headache Prevention in Adults with Chronic Migraine
Industry Symposium: FORWARD Open Label Study: Evaluating the Effectiveness of BOTOX® Compared to Topiramate for Headache Prevention in Adults with Chronic Migraine *
Director The Los Angeles Headache Center, USA; The San Diego Headache Center, San Diego, CA, USA Los Angeles, California, United States
This symposium will discuss: A discussion and in-depth exploration of the latest data driving change in chronic migraine prevention. Review key areas, including: • Pivotal clinical trial data for BOTOX® • Situational Analysis of today’s patient journey and address unmet needs to elevate the standard of care • Deep-dive review of FORWARD Open Label Study- defining effectiveness with efficacy and tolerability; why clinical utility matters in chronic migraine • Latest updates to guidelines and changes to access with payer policies that impact today’s clinics
Sponsored by Abbvie
Learning Objectives:
Upon completion participants will have learnt about the results between commonly used migraine preventive treatments in a head to head study
Upon completion participants will have learnt about the difference between efficacy and effectiveness when comparing different migraine preventive medications
Upon completion participants will have learnt about the limitations of doing head to head comparisons
